Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
Rodríguez-Carrio J, Burska A, Conaghan PG, Dik WA, Biesen R, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Ronnblom L, Vital E, Versnel M. Rodríguez-Carrio J, et al. Among authors: burska a. RMD Open. 2023 Mar;9(1):e002864. doi: 10.1136/rmdopen-2022-002864. RMD Open. 2023. PMID: 36882218 Free PMC article.
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.
Rodríguez-Carrio J, Burska A, Conaghan PG, Dik WA, Biesen R, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Rönnblom L, Versnel MA, Vital EM. Rodríguez-Carrio J, et al. Among authors: burska a. Ann Rheum Dis. 2023 Jun;82(6):754-762. doi: 10.1136/ard-2022-223628. Epub 2023 Mar 1. Ann Rheum Dis. 2023. PMID: 36858821
Type I interferon pathway assays in studies of rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.
Burska A, Rodríguez-Carrio J, Biesen R, Dik WA, Eloranta ML, Cavalli G, Visser M, Boumpas DT, Bertsias G, Wahren-Herlenius M, Rehwinkel J, Frémond ML, Crow MK, Ronnblom L, Conaghan PG, Versnel M, Vital E. Burska A, et al. RMD Open. 2023 Mar;9(1):e002876. doi: 10.1136/rmdopen-2022-002876. RMD Open. 2023. PMID: 36863752 Free PMC article.
An immunological biomarker to predict MTX response in early RA.
Ponchel F, Goëb V, Parmar R, El-Sherbiny Y, Boissinot M, El Jawhari J, Burska A, Vital EM, Harrison S, Conaghan PG, Hensor E, Emery P. Ponchel F, et al. Among authors: burska a. Ann Rheum Dis. 2014 Nov;73(11):2047-53. doi: 10.1136/annrheumdis-2013-203566. Epub 2013 Aug 29. Ann Rheum Dis. 2014. PMID: 23989988
Changes in peripheral blood immune cell composition in osteoarthritis.
Ponchel F, Burska AN, Hensor EM, Raja R, Campbell M, Emery P, Conaghan PG. Ponchel F, et al. Among authors: burska an. Osteoarthritis Cartilage. 2015 Nov;23(11):1870-8. doi: 10.1016/j.joca.2015.06.018. Epub 2015 Jul 8. Osteoarthritis Cartilage. 2015. PMID: 26162804 Free PMC article.
Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis.
Mortimer I, Bissell LA, Hensor EMA, Kozera L, Mackie SL, Burska AN, Nam JL, Keen H, Villeneuve E, Donica H, Buch MH, Conaghan PG, Emery P, Morgan AW, Andrews J. Mortimer I, et al. Among authors: burska an. Rheumatology (Oxford). 2019 Sep 1;58(9):1684-1686. doi: 10.1093/rheumatology/kez114. Rheumatology (Oxford). 2019. PMID: 31329965 Free PMC article. Clinical Trial. No abstract available.
46 results